Thymidylate synthase

CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial

Retrieved on: 
Thursday, December 14, 2023
CV6, Immune system, Drug development, Lung, Cancer, Inflammation, Melanoma, DNA, Mouth, Apyrase, Therapy, MHRA, Royal Marsden Hospital, Thymidylate synthase, Gastrointestinal cancer, University, ECMC, Toxicity, Patient, Safety

Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies including thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU).

Key Points: 
  • Cancer cell DNA uracilation by CV6-168 is aided by combination with standard cancer therapies including thymidylate synthase (TS) inhibitors such as 5-fluorouracil (5-FU).
  • The UK multi-centre Phase 1a clinical trial will combine CV6-168 with infusional 5-FU to treat gastrointestinal cancer patients, such as colon, gastric, and pancreatic cancers as well as other tumor types such as melanoma, lung, and ovarian cancers.
  • The trial is expected to have dosed its first patient in Q1 2024, with trial read-outs expected in H1 2025.
  • CV6 CEO and Founder Dr Robert Ladner said, “This regulatory approval is a key milestone as we progress CV6-168 into a first-in-human Phase 1a clinical trial.

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 16, 2022
Protide, Immunogenic cell death, PD-1, NSCLC, Docetaxel, Oxaliplatin, European Society for Medical Oncology, Large-cell lung carcinoma, Melanoma, Patient, Neoplasm, Adenocarcinoma, Pembrolizumab, Oncology, Irinotecan, Thymidylate synthase, NCNA, Commencement (album), Security (finance), ESMO, Colorectal cancer, Cancer, Therapy, Pemetrexed, Bevacizumab, Organic acid, Pharmaceutical industry, Medical imaging, Food delivery

EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.

Key Points: 
  • EDINBURGH, United Kingdom, Nov. 16, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics.
  • As of September 30, 2022, NuCana had cash and cash equivalents of 50.8 million compared to 46.5 million as of June 30, 2022 and 60.3 million at December 31, 2021.
  • NuCana continues to advance its various clinical programs and reported a net loss of 4.5 million for the quarter ended September 30, 2022, as compared to a net loss of 8.0 million for the quarter ended September 30, 2021.
  • Basic and diluted loss per share was 0.09 for the quarter ended September 30, 2022, as compared to 0.15 per share for the quarter ended September 30, 2021.

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Retrieved on: 
Wednesday, October 26, 2022
ICD, SEC, Company, Squamous cell carcinoma, Security (finance), U.S. Securities and Exchange Commission, Bevacizumab, Damage-associated molecular pattern, NASDAQ, CRC, Private Securities Litigation Reform Act, DNA, Cancer, Lung cancer, Goal, Forward-looking statement, DNA repair, Terminology, Pemetrexed, Large-cell lung carcinoma, Immunotherapy, Docetaxel, Protide, Pembrolizumab, Patient, PD-1, Immunogenic cell death, GLOBE, FOLFIRI, Thymidylate synthase, NCNA, Adenocarcinoma, Vaccine, Pharmaceutical industry, NSCLC

BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.

Key Points: 
  • BARCELONA, Spain, Oct. 26, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced non-clinical data from two poster presentations at the 34th EORTC-NCI-AACR Annual Meeting being held from October 26 to 28, 2022.
  • NUC-3373 generated high intracellular levels of the anti-cancer metabolite FUDR-MP, resulting in TS inhibition, and the DNA-targeting metabolite, FUDR-TP.
  • These data highlight that NUC-3373 may be an effective treatment for non-small cell lung cancer (NSCLC) regardless of histological subtype and basal TS expression.
  • NUC-3373 causes NSCLC cells to release damage associated molecular patterns (DAMPs), molecular signals that activate immune cells leading to immunogenic cell death (ICD).

NuCana Presents Favorable Data on NUC-3373 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Retrieved on: 
Monday, September 12, 2022
Safety, Thymidine, De novo, Uridine, Organic acid, Damage-associated molecular pattern, CRC, FOLFIRI, Patient, U.S. Securities and Exchange Commission, Oncology, Protide, NASDAQ, Dump, ESMO, NCNA, Oxaliplatin, Nucleotide, Bevacizumab, Cytokine, Diarrhea, Mucositis, Annual general meeting, Company, TS, FOLFOX, Toxic leukoencephalopathy, DNA, SEC, Growth hacking, European Society for Medical Oncology, Capecitabine, Irinotecan, Forward-looking statement, Acral lentiginous melanoma, Neutropenia, University of Washington School of Medicine, Associate professor, Goal, Progression-free survival, Security (finance), GLOBE, Immune system, Thymidylate synthase, Colorectal cancer, Private Securities Litigation Reform Act, Docetaxel, Cancer, Fred Hutchinson Cancer Research Center, Terminology, PD-1, University, PFS, Medical imaging, Pharmaceutical industry

PARIS, Sept. 12, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data from the ongoing NuTide:302 study of NUC-3373 in combination with other agents at the European Society for Medical Oncology (ESMO) Annual Meeting being held from September 9 to 13, 2022.

Key Points: 
  • Data presented at ESMO describe NUC-3373 plus leucovorin in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI) in the dose-finding part of the study.
  • The disease control rates for the NUFOX and NUFIRI regimens were 80% and 55%, respectively.
  • With these data, NuCana has established the recommended Phase 2 dose for NUC-3373 as part of NUFOX and NUFIRI regimens.
  • TS is required to convert uridine (specifically dUMP) to thymidine (specifically dTMP), one of the four nucleotides that comprise DNA.

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Tuesday, September 6, 2022
European Society for Medical Oncology, Uridine, Security (finance), Protide, Diarrhea, Safety, Thymidine, RNA, Cancer, Gene, NASDAQ, Paris Expo Porte de Versailles, NCNA, Adenosine, Irinotecan, Nucleotide, ESMO, Dump, Thymidylate synthase, DNA, TS, SEC, Growth hacking, U.S. Securities and Exchange Commission, De novo, Goal, PD-1, GLOBE, Company, Cordycepin, Oncology, ADA, Oxaliplatin, Capecitabine, Neutropenia, Mucositis, Cell death, CRC, Congress, Polyadenylation, Terminology, Private Securities Litigation Reform Act, Transport, Forward-looking statement, Patient, Acral lentiginous melanoma, Medical imaging, Pharmaceutical industry

EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 06, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2022 being held September 9-13, 2022 at the Paris Expo Porte de Versailles in Paris, France.
  • TS is required to convert uridine (specifically dUMP) to thymidine (specifically dTMP), one of the four nucleotides that comprise DNA.
  • The inhibition of TS results in an imbalance in the ratio of dUMP and dTMP, thereby disrupting DNA synthesis and repair, ultimately leading to cancer cell death.
  • Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements.

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Tuesday, March 8, 2022
NASDAQ, AACR, ICD, Protide, Private Securities Litigation Reform Act, Company, Colorectal cancer, Diarrhea, U.S. Securities and Exchange Commission, Survival, Fluorodeoxyuridylate, NCNA, Thymidylate synthase, Cancer, Mucositis, Immunogenic cell death, Aplastic anemia, GLOBE, Patient, Security (finance), American Association, Damage-associated molecular pattern, 2021 Essex County Council election, American Association for Cancer Research, SEC, Nivolumab, Goal, RNA, Terminology, Forward-looking statement, CRC, Vaccine, Pharmaceutical industry

EDINBURGH, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the release of two abstracts to be presented as posters at the American Association of Cancer Research (AACR) Annual Meeting being held from April 8 to 13, 2022.

Key Points: 
  • EDINBURGH, United Kingdom, March 08, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the release of two abstracts to be presented as posters at the American Association of Cancer Research (AACR) Annual Meeting being held from April 8 to 13, 2022.
  • NUC-3373 and 5-FU exert their anti-cancer effects through the metabolite, FUDR-MP (or FdUMP), which inhibits thymidylate synthase (TS), a critical enzyme for cancer cell growth and survival.
  • Pre-clinical and clinical data show that NUC-3373 generates far higher levels of FUDR-MP than 5-FU and is more effective at inhibiting TS activity.
  • Through a more targeted, DNA-directed pathway, NUC-3373 may provide, if approved, a potentially more effective, safer and convenient therapeutic option than 5-FU for patients with cancer.

NuCana Announces Four Poster Presentations at the ESMO Congress 2021

Retrieved on: 
Thursday, September 16, 2021
U.S. Securities and Exchange Commission, Security (finance), NCNA, Protide, NDA, European Society for Medical Oncology, Poster, Neutropenia, Forward-looking statement, Overalls, Plasma, Patient, ESMO, Company, Thymidylate synthase, Private Securities Litigation Reform Act, Acral lentiginous melanoma, Organic acid, Half-life, Financial toxicity, Terminology, ORR, NASDAQ, Pharmacokinetics, Progression-free survival, Neoplasm, Colorectal cancer, Endpoint security, Diarrhea, GLOBE, Cisplatin, Population, Goal, SEC, Cholangiocarcinoma, Cancer, Oncology, Congress, Medical imaging, Pharmaceutical industry

EDINBURGH, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced the presentation of four posters at the European Society for Medical Oncology (ESMO) Congress 2021. The Company presented additional data from the ongoing Phase 1b/2 study of NUC-3373 in combination with standard therapies in patients with advanced colorectal cancer (NuTide:302), final data from the Phase 1 study of NUC-3373 in patients with advanced solid tumors (NuTide:301), and additional interim data from the Phase 1 study of NUC-7738 in patients with advanced solid tumors. The Company also presented a trials-in-progress poster describing the ongoing Phase 3 study of Acelarin plus cisplatin in patients with advanced biliary tract cancer.

Key Points: 
  • EDINBURGH, United Kingdom, Sept. 16, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), announced the presentation of four posters at the European Society for Medical Oncology (ESMO) Congress 2021.
  • The Company also presented a trials-in-progress poster describing the ongoing Phase 3 study of Acelarin plus cisplatin in patients with advanced biliary tract cancer.
  • Looking ahead to the remainder of 2021 and first half of 2022, we have multiple milestones that we plan to announce.
  • Details of NuCanas e-poster presentations during the ESMO Congress 2021 being held September 16-21, 2021 are as follows:
    NuCana presented two posters on NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), one of the most widely used anti-cancer medicines.

NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

Retrieved on: 
Saturday, April 10, 2021
Clinical medicine, Cancer, Medicine, Organofluorides, Oncology, Thymidylate synthase, Fluorouracil, Colorectal cancer, Chemotherapy

EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021.

Key Points: 
  • EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021.
  • NuCana presented two posters on NUC-3373, its ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU), a very widely used anti-cancer drug.
  • Poster Title: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer
    This poster describes further encouraging interim data from 38 patients with metastatic colorectal cancer.
  • The second NUC-3373 poster showed that NUC-3373-treated colon cancer cells are able to activate a natural killer (NK) cell response.

NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer

Retrieved on: 
Friday, January 15, 2021
Pyrimidines, Drugs, Chemical compounds, Organofluorides, Prodrugs, Thymidylate synthase, Capecitabine, Fluorouracil, Colorectal cancer

NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.

Key Points: 
  • NuTide:302 is a three-part study investigating NUC-3373, NuCanas targeted thymidylate synthase inhibitor, in heavily pre-treated patients with metastatic colorectal cancer.
  • The ASCO GI presentation highlighted data from 37 patients treated in Part I of the study who received NUC-3373 either as monotherapy or in combination with leucovorin.
  • Many patients achieved longer progression-free survival on NUC-3373 than they had on their prior line of therapy and five patients experienced tumor shrinkage.
  • Our objective is to replace 5-FU and capecitabine with NUC-3373 as the backbone of treatment for patients with colorectal cancer.

NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

Retrieved on: 
Friday, May 15, 2020
Medical specialties, Medicine, Thymidylate synthase, Clinical medicine, Damage-associated molecular pattern, PD-L1, Cancer, Cancer treatments, Mutation, Antineoplastic resistance, Thymidylate synthase inhibitor

In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.

Key Points: 
  • In prior non-clinical studies, Acelarin has shown an ability to cause cancer-cell death via DNA damage.
  • These new in vitro data presented at AACR suggest that Acelarin may also have a potential immunomodulatory role.
  • Acelarin was found to cause the release of Damage Associated Molecular Patterns, or DAMPs, and increase the expression of PD-L1 on cancer cells.
  • NUC-3373 was found to be a potent inhibitor of thymidylate synthase, which results in DNA damage of cancer cells.